This study sought to evaluate the impact of chronic kidney disease (CKD) on coronary atherosclerotic plaque composition, morphology, and outcomes in patients with acute coronary syndromes (ACS).
P atients with chronic kidney disease (CKD) presenting with an acute coronary syndrome (ACS) are at substantially increased risk for adverse fatal and nonfatal cardiovascular events compared with those patients with preserved renal function (1) (2) (3) . This excess risk persists despite treatment with contemporary pharmacotherapy and early revascularization (4) and is not accounted for by traditional risk factors (5) . Classically, the increased cardiovascular risk among patients with See page S73 advanced renal failure on dialysis has been attributed to a state of "accelerated atherosclerosis" (6) . Whether this is true in the much larger group of patients with less advanced CKD remains unknown. In this regard, several recent studies using both invasive and noninvasive imaging modalities have suggested that there are no differences in either the extent or progression of atherosclerosis between patients with and without CKD (7, 8) . Clarifying this issue is clinically relevant as up to 40% of all patients presenting with ACS have some degree of renal impairment (2, 3) . The detection of high-risk plaque subtypes and underlying coronary atherosclerotic plaque composition is now possible with grayscale and radiofrequency intravascular ultrasound (IVUS) (9, 10) . Differences in IVUSrelated parameters of coronary atherosclerosis in patients with versus without CKD might provide important insights into the increased risk of these patients. Accordingly, we sought to compare coronary plaque extent, morphology, composition, and clinical outcomes in patients enrolled in the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study according to baseline renal function.
M E T H O D S
The PROSPECT study design, major inclusion and exclusion criteria, endpoints, and definitions have been previously described in detail (11, 12) and results presented (13) (14) (15) (16) (17) (18) . In brief, 697 patients with ACS (ST-segment elevation myocardial infarction beyond 24 h [STEMI], non-STEMI, or unstable angina) undergoing percutaneous coronary intervention (PCI) of 1 or 2 major epicardial coronary arteries underwent 3-vessel multimodality intracoronary imaging (quantitative coronary angiography, grayscale IVUS imaging, and radiofrequency IVUS [virtual histology-intravascular ultrasound (VH-IVUS), Volcano Corporation, San Diego, California]) in order to prospectively characterize the proximal 6 to 8 cm of the coronary tree prior to longitudinal follow-up. Patients were enrolled (and imaging was performed) only after performance of successful and uncomplicated PCI of all coronary lesions responsible for the index event, and after completion of any other planned interventions. Exclusion criteria included serum creatinine Ͼ2.5 mg/dl, presentation with hypotension, shock or left ventricular ejection fraction Ͻ30%, left main coronary artery culprit lesion, or necessity for PCI in all 3 major epicardial coronary vessels. Patients with moderate to severe elevations of serum creatinine (Ն2.5 mg/dl) were excluded to minimize risk for further renal deterioration following additional contrast exposure during post-PCI IVUS imaging. Serum creatinine, fasting lipid panel and glucose, hemoglobin A1c, and highsensitivity C-reactive protein were measured at baseline. The present study includes patients in whom serum creatinine was measured at baseline and whose data was available to determine renal function (n ϭ 646).
Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal 
Disease formula and CKD was defined as an eGFR Ͻ60 ml/min/1.73 m 2 (19) . Patients underwent clinical follow-up at 30, 180, and 365 days, and then yearly for at least 2 years (median follow-up was 3.4 years). An independent clinical events committee blinded to baseline features and imaging results adjudicated all clinical events as due to recurrence at the original treated (culprit) lesion, at a previously untreated nonculprit lesion, or at an undetermined lesion location (when follow-up angiography was not performed). All baseline and follow-up angiograms and IVUS images were analyzed at an independent core angiographic laboratory by technicians who were blinded to clinical outcomes (Cardiovascular Research Foundation, New York, New York). Angiographic qualitative and quantitative measurements were obtained for the entire coronary tree. All angiographic lesions with at least 30% visible diameter stenosis were analyzed. An IVUS lesion was defined as at least 3 consecutive frames with a plaque burden of at least 40%. Such lesions were further classified by means of VH-IVUS as one of the following: thin-cap fibroatheroma (TCFA), thick-cap fibroatheroma, pathological intimal thickening, fibrotic plaque, or fibrocalcific plaque (11, 20) . Each grayscale and VH-IVUS frame and lesion was coregistered to the angiographic roadmap using fiduciary branches for alignment, as previously described (11, 20) .
The primary endpoint of interest in the PROSPECT study was nonculprit lesion-related major adverse cardiac events (MACE) defined as the composite of cardiac death, cardiac arrest, myocardial infarction, or rehospitalization due to unstable or progressive angina. Cardiac death was defined as death due to immediate cardiac cause and included unwitnessed death and death of unknown cause. Stent thrombosis was defined using the Academic Research Consortium criteria as definite or probable (21) . The timing of stent thrombosis following index PCI was further categorized as acute (24 h), subacute (1 to 30 days), and late (30 days to 1 year).
The study was approved by the institutional review board at each participating center, and all patients signed informed, written consent. Informed consent was obtained after the patient was stabilized prior to the catheterization procedure. Statistical analysis. Baseline demographics, imaging characteristics, and outcomes were compared according to the presence of CKD. Categorical variables were summarized using percentages and counts and were compared using chi-square tests or Fischer exact test (cell size Ͻ5) where appropriate. Continuous variables were summarized as median with interquartile range or mean Ϯ SD and compared using the nonparametric Wilcoxon rank sum test. Multivariable analyses using CKD lesions as exposures of interest were performed using generalized estimating equations, which allowed for simultaneous adjustment of both patientand lesion-level variables. This method also controls for correlated data as multiple lesions can arise from the same patient. Outcomes were summarized as Kaplan-Meier estimates and compared using log-rank tests. A p value of Ͻ0.05 was considered statistically significant. All statistical analyses were performed using SAS (version 9.2, SAS Institute Inc., Cary, North Carolina). Table 1 . In addition to being older, patients with CKD were more likely to be women, diabetic, have higher body mass index, and have a history of congestive heart failure. Other cardiovascular risk factors, including hypercholesterolemia and hypertension, were more common in patients with CKD. Presentation with recent STEMI was less frequent whereas non-STEMI was more common in CKD patients. The number of angiographic lesions as determined by quantitative coronary angiography per patient and the frequency of 3-vessel disease were similar in CKD and non-CKD groups ( The total number of vessels that underwent multimodality imaging in patients with and without CKD were 218 and 1,700, respectively (Table 2) . Mean external elastic membrane and lumen cross-sectional area (CSA) (normalized for imaged length) were smaller in CKD vessels and mean plaque and media CSA did not differ between groups. By radiofrequency IVUS, the percentage of plaque consisting of dense calcium and necrotic core was higher whereas the percentage of fibrous and fibrofatty volume was less in CKD versus non-CKD vessels (Table 2) . Lesion-level IVUS analysis. By IVUS, 280 discrete nonculprit lesions were characterized in the 73 patients with CKD, and 2,390 lesions were evaluated in the 573 patients without CKD. As shown in Table 3 , lesions in patients with CKD were longer and had greater plaque burden and smaller luminal areas. The frequencies of lesions with a minimum luminal area Յ4.0 mm 2 , plaque burden Ն70%, and lesion length greater than the median of 11.2 mm were greater in patients with CKD compared to those without CKD (Fig. 1) . The external elastic membrane area and remodeling index were also smaller in the CKD versus non-CKD lesions. Plaque composition also varied by level of renal function with greater necrotic core and dense calcium in CKD lesions. There were no significant differences in the frequency of lesion classification by radiofrequency IVUS in patients with versus without CKD. The percentage of lesions with a necrotic core volume Ͼ10% (median) was significantly higher while those with a fibrous tissue volume Tables 1 and 2 .
Ͼ60% (median) was lower in patients with versus without CKD (Fig. 2) . By multivariable analysis, lesions in patients with CKD versus those in patients without CKD were more likely to have a plaque burden Ն70% and minimum luminal area Յ4.0 mm 2 , whereas the association between CKD lesion and long length (greater than the median of 11.2 mm) was attenuated following adjustment (Table 4) . After multivariable adjustment, CKD lesions were significantly more likely to be composed of necrotic core volume Ͼ10% (median) and less likely to consist of fibrous tissue volume Ͻ60% (median) ( Table 4) . As calcification can interfere with the radiofrequency IVUS interpretation of plaque composition, these analyses were repeated after excluding lesions with dense calcium percentage greater than the 75th percentile yielding similar results. There was a nonsignificant 1.47-fold higher odds for CKD lesion classification as a TCFA (Table 4) . Follow-up adverse events. As shown in Table 5 , patients with versus those without CKD had higher cumulative 3-year rates of cardiac death and composite cardiac death, arrest, or myocardial infarction. All-cause mortality was also significantly higher in CKD than in non-CKD patients (12.0% vs. 2.5%; p Ͻ 0.0001). The frequency of rehospitalization for unstable or progressive angina did not differ significantly between the 2 groups, whereas the overall MACE was significantly greater in patients with versus without CKD (31.7% vs. 19.2%; p ϭ 0.01). Although the incidence of nonculprit or culprit adverse events did not differ significantly between groups, indeterminate events were more common among CKD than non-CKD patients (12.5% vs. 1.3%; p Ͻ 0.0001).
D I S C U S S I O N
In the present analysis of 646 patients with ACS who underwent successful PCI followed by 3-vessel grayscale and radiofrequency IVUS, we detected important differences in the extent of coronary atherosclerosis and coronary plaque morphology between patients with and without CKD. Lesions in CKD patients were longer with greater luminal encroachment and higher plaque burden compared with their non-CKD counterparts. Moreover, coronary atherosclerotic plaque composition assessed with radiofrequency IVUS demonstrated greater necrotic core and dense calcium with less fibrous tissue in CKD versus non-CKD lesions, whereas there were no significant differences in lesion classification. Nonculprit lesion-related MACE occurred with similar frequency during 3-year follow-up in patients with and without CKD, although CKD patients had significantly greater overall rates of all-cause and cardiac death and composite cardiac death, arrest, or myocardial infarction. In aggregate, our results suggest that renal dysfunction not only results in greater coronary atherosclerotic plaque burden and luminal encroachment, but it may also modulate coronary atherosclerotic plaque composition to a less stable phenotype. These data, therefore, provide novel insight into mechanisms of greater atherothrombotic risk in CKD patients presenting with ACS.
Existing data evaluating coronary atherosclerosis in CKD patients using imaging modalities other than conventional angiography are sparse. Two small reports involving patients without ACS who CKD ϭ chronic kidney disease; TCFA ϭ thin-cap fibroatheroma(s).
underwent conventional (grayscale) IVUS reported that the luminal CSA was smaller in CKD than in non-CKD lesions (7, 8) . Similarly, we also found that a minimum lumen area Յ4.0 mm 2 was significantly more common in CKD lesions (odds ratio: 1.60, 95% confidence interval: 1.13 to 2.27). These findings are clinically relevant as a smaller luminal CSA not only confers greater ischemic potential (22, 23) , but it might also indicate predisposition to cardiac death. In an autopsy series, Burke et al. (24) found severe luminal stenosis without superimposed thrombus in 54 of 113 men (47%) who died suddenly, suggesting that nonthrombotic mechanisms, such as arrhythmias, may underlie many cases of sudden cardiac death in the setting of severe luminal stenosis. Given the increased frequency of severe stenoses in patients with CKD (which are often angiographically inapparent), such a mechanism may contribute to the worsened prognosis of CKD patients.
In addition to greater luminal encroachment, we also found that the overall extent of coronary atherosclerosis was greater in CKD than in non-CKD patients. By IVUS, CKD lesions were longer and more likely to have plaque burden Ͼ70%. These findings are consistent with several smaller studies documenting a greater burden of angiographic coronary artery disease in CKD than in non-CKD patients presenting with ACS (4,25). As greater plaque burden was identified in PROSPECT to be a powerful predictor of subsequent lesion-related events (11), this finding might place CKD patients at higher risk for future ACS. In contrast to the present report in patients with ACS, other studies have found no significant differences in atherosclerotic burden between non-ACS patients with and without renal impairment (7, 8, 26, 27) .
Using radiofrequency IVUS, we identified several differences in coronary atherosclerotic plaque composition between patients with and without CKD. Our findings of higher amounts of dense calcium in CKD lesions is not surprising given the strong and established association between renal insufficiency and increased coronary calcification (28) , possibly due to secondary hyperparathyroidism. A novel finding from the present analysis, however, is that, compared with non-CKD lesions, CKD lesions (30) found that collagenous fibers in carotid plaque were significantly less frequent in CKD versus non-CKD patients (39.2% vs. 54.6%, p ϭ 0.001). Although these reports were limited by lack of adequate adjustment and potential for bias, we conducted extensive multivariable adjustment for both clinical and lesion-level differences in our statistical models. Moreover, our results with radiofrequency IVUS did not change after excluding lesions with the most severe levels of calcification. Finally, all images in the PROSPECT study were analyzed in a blinded core lab, thereby minimizing measurement bias. Our findings suggest unique and independent mechanisms not accounted for by traditional covariates that may alter atherosclerotic plaque composition in the setting of CKD. Serum levels of matrix metalloproteinases, for example, are elevated in patients with moderate to severe renal impairment (30, 31) and are associated with plaque progression and fibrous cap degradation (32, 33) . In addition, experimental data suggest that CKD potentiates foam cell generation by enhancing macrophage entry into the vascular wall and inhibiting cholesterol efflux (34, 35) . These putative pathways provide a biologic rationale for our clinical observations of greater necrotic core and less fibrous tissue in coronary atherosclerotic plaque from CKD versus non-CKD lesions. Further investigation is clearly warranted to fully characterize the unique atherosclerotic phenotype of CKD.
Consistent with earlier studies, the cumulative 3-year rates of all-cause and cardiac mortality were substantially higher in CKD than non-CKD patients (1, 26, 36) . Adverse events attributable to nonculprit lesions, however, did not differ significantly between the 2 groups. Conversely, indeterminate lesions were responsible for greater rates of MACE, particularly cardiac death, during follow-up among patients with CKD. We are unable to determine whether or not these events were the result of nonculprit lesion plaque rupture or culprit-lesion stent thrombosis, because angiography was not performed in these patients. The exact etiology of higher cardiac death in CKD patients in the present study, therefore, remains speculative based on our results. Study limitations. Relatively few patients had CKD, and the number of adverse events in the CKD cohort was small. Therefore, the present results should be considered exploratory and hypothesis generating. Patients with severe renal insufficiency were also excluded from enrollment, and thus the CKD cohort represents mild to moderate renal dysfunction. We did not assess renal function at follow-up, and thus some patients with acute kidney injury may have been misclassified as CKD. Nor was urinary albumin measured, which might have allowed further risk stratification. VH-IVUS may overestimate the frequency of TCFA as IVUS has an axial resolution of ϳ150 m, whereas the pathologic definition of TCFA typically requires cap thickness Ͻ65 m (37). Additional limitations include lack of information on infarct size and ST-segment resolution following PCI, which might also contribute to different rates of MACE between CKD and non-CKD in the setting of myocardial infarction. Although patients with severe left ventricular dysfunction (ejection fraction Ͻ30%) were excluded from the present study, we were unable to evaluate the differences in moderate left ventricular dysfunction between CKD and non-CKD groups, as this information was not collected. Another limitation is the lack of propensity matching in our statistical methods.
C O N C L U S I O N S
Despite these limitations, the present report is the most comprehensive and detailed characterization of coronary atherosclerotic plaque morphology in CKD patients presenting with ACS using a validated in vivo imaging modality, which has been shown to predict future lesion-specific cardiac events (11) . As cardiovascular risk is significantly increased in patients with renal dysfunction, particularly in the setting of ACS, our findings merit additional prospective evaluation and clinical correlation.
